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In this work, graphene oxide–based tablets (GO-Tabs) were prepared by applying a
thin layer of functionalized GO on a polyethylene substrate. The GO was
functionalized with amine groups (–NH2) by poly(ethylene glycol)bis(3-aminopropyl)
terminated (GO-NH2-PEG-NH2). The functionalized GO-Tabs were used for the
extraction of ritonavir (RTV) in human saliva samples. RTV in plasma and saliva
samples was analyzed using LC–MS/MS. Gradient LC system with MS/MS in the
positive-ion mode [electrospray ionization (ESI+)] was used. The transitions m/z
721 ! 269.0 and m/z 614 ! 421 were used for RTV and the internal standard
indinavir, respectively. This study determined the human immunodeficiency virus
protease inhibitor RTV in human saliva samples using functionalized GO-Tab and
LC–MS/MS, and the method was validated. The standard calibration curve for plasma
and saliva samples was constructed from 5.0 to 2000 nmol L1. The limit of
detection was 0.1 nmol L1, and the limit of quantification was 5.0 nmol L1 in both
plasma and saliva matrices. The intra- and inter-assay precision values were found to
be between 1.5 and 5.8%, and the accuracy values ranged from 88.0 to 108%
utilizing saliva and plasma samples. The extraction recovery was more than 80%, and
the presented functionalized GO-Tabs could be reused for more than 10 extractions
without deterioration in recovery.
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1 | INTRODUCTION
Ritonavir (RTV, Figure 1) is an anti-human immunodeficiency virus
(HIV) drug that belongs to the HIV protease inhibitor group with a
unique combination of potency, selectivity, and oral bioavailability
(Kempf et al., 1995). RTV exhibits potent in vitro activity against
laboratory and clinical strains of HIV-1 [50% effective concentration
(EC) = 0.022–0.13 μM] and HIV-2 (EC = 0.16 μM) (Marsh, Eiden, &
McDonald, 1997). It has been shown that RTV can cause marked
reductions in plasma viral load, particularly when used in combination
with other protease inhibitors (Frappier et al., 1998). Meanwhile, RTV
combined with lopinavir has shown activity against SARS-CoV-1 for
immediate clinical use in many countries and has also been suggested
as a treatment option against Covid-19 (Dalerba, Levin, &
Thompson, 2020). Combinations of antiretroviral agents are being
used to manage patients with HIV disease by attempting to improve
the extent and duration of antiretroviral activity and, therefore, clinical
benefit, as well as limiting the development of viral resistance and
drug intolerance. Pharmacokinetic evaluation and efficacy study of
drugs need to develop and validate sensitive and selective
bioanalytical methods for their determination in biological samples as
well as formulations. Various analytical methods, such as HPLC,
LC–MS, high-performance thin-layer chromatography, and UV
spectroscopy, have been reported for the determination of RTV in
pharmaceutical and biological fluids (Dias, Bergold, & Fröehlich, 2009;
Dias, Rossi, Donato, Bergold, & Fröehlich, 2005; Estrela, Ribeiro,
Seixas, & Suarez-Kurtz, 2008; Rathnasamy, Karuvalam, Pakkath,
Kamalakannan, & Sivasubramanian, 2018; Ray, Pang, & Carey, 2002).
Due to the complexity of biological samples, sample preparation
has a vital function in bioanalysis progression (Moein, El Beqqali, &
Abdel-Rehim, 2017).
Therefore, there is an increasing need for new sample preparation
techniques that are simple and efficient in the isolation of target
analytes and environmentally friendly.
Solid-phase extraction (SPE) has been recognized as an
efficient and reduced solvent consumption sample preparation
procedure for a wide range of samples, as highlighted by several
reviews (Abdel-Rehim et al., 2020; Ashri & Abdel-Rehim, 2011; Wen,
Chen, Li, Liu, & Chen, 2014). The selectivity and efficiency of SPE
procedures are mainly dependent on the proper choice of the
sorbent material. In the past few years, nanomaterials (NMs)
have been considered as a selective and efficient adsorbent in
SPE and found wide applications in bioanalytical methods (Ahmadi,
Elmongy, Madrakian, & Abdel-Rehim, 2017; Zhang, Zheng, Li, &
Lin, 2013).
Among various NMs, graphene oxide (GO) has gained wide
attention as a sorbent because of its improved water dispersibility,
high surface area, high mechanical strength, and versatile surface
modification (Ahmadi, Elmongy, Madrakian, & Abdel-Rehim, 2017).
The surface modification of the NMs with special functional
groups can significantly improve the stability and selectivity of
adsorbents and increase the driving force of extraction. Generally,
nanoadsorbents are packed inside cartridges, syringe barrels, micro-
columns, and pipette tips. Also, nanoadsorbents can be coated on stir
bars, silica fibers, and capillary columns (Fan, He, Wu, Chen, &
Hu, 2015; Wang, Knobel, Wilson, Calimag-Williams, & Campiglia,
2011; Vatani & Yazdi, 2014).
In addition, the nanoadsorbents can be deposited on the surface
of polymeric tablets. Recently, our research group has successfully
applied polyethylene tablet–based Molecularly imprinted polymer and
GO for separation and preconcentration of amphetamine and omepra-
zole in biological samples (El-Beqqali & Abdel-Rehim, 2016; Zohdi,
Hashemi, Uheida, Moein, & Abdel-Rehim, 2019). Polyethylene acts as
a porous scaffold for nanoadsorbents and provides a uniform and
repeatable surface area for target analytes. Also, they can be prepared
in varying sizes, from large to small, to fit the volume of samples and
the amount of sorbent required for quantitative extraction of the
analyte. The aim of this study was to prepare a new tablet-form
adsorbent based on the incorporation of modified GO into polyethyl-
ene tablets for separation and determination of RTV in plasma
and saliva samples using LC–MS/MS. Poly(ethylene glycol)bis
(3-aminopropyl) terminated (NH2-PEG-NH2) was used for modifica-
tion. Multiple hydrogen bonds and NH-π interactions between
nanocomposite and target analytes provide a strong driving force for
extraction. The main factors affecting extraction efficiency were
investigated and optimized. The developed method was applied for
the determination of RTV in human saliva and plasma with good
accuracy and acceptable precision.
F IGURE 1 Molecular structure of ritonavir
and internal standard
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2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
RTV and indinavir [IS (internal standard), purity >98%] (Figure 1),
GO, and poly(ethylene glycol)bis(3-aminopropyl) were purchased
from Sigma-Aldrich (Steinheim, Germany). HPLC-grade acetonitrile,
HPLC-grade methanol, formic acid, and ammonium hydroxide were
acquired from Merck (Darmstadt, Germany).
2.2 | Instrumentation
Two Shimadzu pumps (LC-10ADvp, Kyoto, Japan) and autosampler
CTC-Pal (Analytics AG, Zwingen, Switzerland) were employed for the
LC system. The LC column was Zorbax Bonus-RP (100  2.1 mm,
3.5 μm) and obtained from Agilent (Palo Alto, CA, USA). A gradient
mobile phase was employed: phase A, 0.2% formic acid in acetoni-
trile/water (0.5:99.5 v/v), and phase B, 0.2% formic acid in acetoni-
trile/water (80:20 v/v). The gradient started from 30 to 90% of phase
B in 5 min, and after 2 min at 90%, it was resetting again to 30%. The
flow rate was held constant at 0.6 mL min1.
A Quatro-micro mass spectrometry (Waters, Manchester, UK)
was utilized. The temperatures of the source block and desolvation
were 150 and 350C, respectively. Nitrogen was used as the
nebulizing gas (950 L h1), and argon was used as the collision gas.
RTV was quantified using multiple reaction monitoring transitions of
m/z 721 ! 269.0 for RTV and m/z 614 ! 42 for the IS. The data
were analyzed using MassLynx 4.1 software.
A ZEISS ULTRA55 field-emission scanning electron microscope
running at 3 kV was used to study the surface morphology of
GO-Tabs. The samples were coated with a thin layer of gold
nanoparticles previously to improve image resolution.
2.3 | Preparation of GO-NH2-PEG-NH2 tabs
Blank polyethylene tablets (9  2 mm) were washed with 1.0 M HCL
and then NaOH (1.0 M) in an ultrasonic bath for 10 min and finally
washed with water and dried at room temperature. GO (20 mg) was
steadily added to 20 mL of acetonitrile under ultrasonication for
30 min. Then, 25 mg of poly(ethylene glycol)bis(3-aminopropyl)
terminated was added slowly to GO solution, and 15 polyethylene
tablets were placed in the solution under sonication for 4 h. Finally,
tablets were removed and placed in a freeze-dryer overnight. The
structure of GO-NH2-PEG-NH2 is shown in Figure 2. Each tablet had
about 2 mg of GO-NH2-PEG-NH2.
F IGURE 2 Preparation of GO-Tabs (graphene oxide–based tablets)
F IGURE 3 Scanning electron micrographs (SEM) of tablets (a) before and (b) after polymerization
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F IGURE 4 (a) Effect of extraction
time on extraction recovery
(2000 nmol L1, saliva sample). (b) Effect
of desorption time on extraction
efficiency (2000 nmol L1, saliva sample).
(c) Effect of sample pH (2000 nmol L1,
saliva sample); buffer solutions were used,
and pH was adjusted by the addition of
base or acid solutions (extraction
efficiency expressed as peak area, n = 3)
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2.4 | Preparation of RTV calibration solutions
The standards were prepared from a stock solution of 100 μM in the
series 5, 10, 20, 50, 100, 250, 500, 1000, 1500, and 2000 nmol L1.
The quality control (QC) samples were prepared at three levels as
follows: QC low (QCL, 15 nM), QC medium (QCM, 900 nM), and QC
high (QCH, 1600 nM). All standards and QC samples were prepared in
pooled saliva and plasma samples. The standards were prepared daily
for each validation assay, though QC samples were stored at 20C
until further analysis. The internal standard concentration was
500 nmol L1.
2.5 | Sample preparation
The sample and IS (200 μL each) were mixed and diluted four times
with water and centrifuged for 3 min. GO-Tab was added to the
sample under agitation for 10 min, and then the mixture was collected
and washed with water (200 μL). Finally, the analytes were desorbed
by constant agitation in 1.0 mL of methanol for 1 min. The methanol
was evaporated, the sample was dissolved in 200 μL of the mobile
phase, and 50 μL was injected into the LC injector.
2.6 | Method validation
The proposed method was validated according to FDA guidelines
(Food and Drug Administration. United States, 2001) and
included accuracy, precision, matrix effect, selectivity, linearity, and
recovery.
QC samples at three different levels, QCL, QCM, and QCH
(n = 6), were used for the determination of precision and accuracy of
the method. For intra-day precision and accuracy, a single analytical
batch was analyzed. On the contrary, three different batches with
three triplicates were analyzed for the evaluation of the inter-day
precision and accuracy. The accepted data for the precision with
relative standard deviation (RSD) should be within ±15%, and the
accuracy with relative error (RE) from the nominal values should not
exceed 15 and 20% for lower limit of quantitation (LLOQ).
The calibration curve range was from 5.0 to 2000 nmol L1. Each
backcalculated standard concentration should not be more than
two-thirds of the points to be accepted with %RSD ≤ 15% except the
lowest concentration (≤20%).
3 | RESULTS AND DISCUSSION
In the present investigation, functionalized GO (GO-NH2-PEG-NH2)
was prepared in tablet form (GO-Tabs) (Figure 2). The GO-Tabs were
applied for the extraction of RTV in human saliva and plasma samples.
The parameters that affect the extraction, such as extraction and
desorption times, sort of desorption solution and sample, were
considered to achieve the greatest extraction recovery.
3.1 | Tablet morphology
As mentioned previously, GO-NH2-PEG-NH2 was absorbed into the
polyethylene surface of a thin film. Figure 3 shows SEM images before
(Figure 3a) and after (Figure 3b) GO-NH2-PEG-NH2 addition.
Figure 3a shows the polyethylene surface that becomes covered with
the GO-NH2-PEG-NH2 (Figure 3b). The average diameter of the
GO-NH2-PEG-NH2 nanoparticles is 50 nm, with a few bigger
particles having an average diameter of 800 nm (Figure 3b).
3.2 | Optimization of extraction procedures
3.2.1 | Influence of extraction time
The extraction time is an important factor, and therefore, the
influence of the extraction time was examined at different times from
3.0 to 30.0 min. The extraction recovery was improved significantly
up to 10.0 min before dropping. Figure 4a shows the dependence of
extraction efficiency on the extraction time.
F IGURE 5 Adsorption capacity of GO-Tabs
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F IGURE 7 MRM transitions obtained from the analysis of a blank sample and ritonavir at 15 nmol L–1 (QCL) with internal standard
(plasma sample)
F IGURE 6 Specificity of the graphene oxide–
based tablets (GO-Tabs): extraction recovery of
GO-Tabs and polyethylene blank tablet
(2000 nmol L–1, saliva sample)
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3.2.2 | Influence of desorption time
Desorption of RTV from GO-Tabs was studied at different times from
1.0 to 20.0 min. More than 50% of the analyte was desorbed after
1.0 min (Figure 4b).
3.2.3 | Effect of sample pH and desorption
solvent type
The influence of sample pH on extraction efficiency was studied at
three different pH values: low (pH: 3), neutral (pH: 7.4), and high
(pH: 12). For pH study, buffer solutions were used (phosphate buffer
for pH 3 and 7.4 and ammonium hydroxide for pH 12). The best
recovery was accomplished at neutral pH (Figure 4c). It has been
reported that RTV is a weak base and not a weak acid with pKa values
of 2.8 and 13.6 (Antimicrobial Agents and Chemotherapy, April 2000,
pp. 1117–1118). The acidity of RTV refers to a deprotonated thiazole
group, whereas the basicity refers to an amine group. Therefore, the
neutral pH showed better effect on the extraction efficiency.
The effect of solvent type on desorption of RTV from GO-Tabs
was studied utilizing different solvents, as well as methanol, mixture
of methanol and water, and acetonitrile. Pure methanol yielded the
highest extraction recovery.
3.3 | The adsorption capacity of the GO-Tabs
The adsorption capacity was studied against sample concentration
at different levels from low (0.1 μmol L1) to high (20.0 μmol L1)
in saliva and plasma samples. As shown in Figure 5, the extraction
recovery in saliva was proportional to a concentration up to
10.0 μmol L1 and then nonlinear. A similar result was obtained with
plasma matrix.
3.4 | Specificity of the GO-Tabs
The specificity of GO-Tabs was investigated by comparing the
extraction of RTV using GO-Tabs with uncovered polyethylene
tablets. The extraction recovery using GO-Tabs was at least fourfold
greater compared with blank polyethylene tablets (Figure 6).
3.5 | Validation procedures
As mentioned earlier, the method was validated in accordance with
FDA guidelines (Food and Drug Administration. United States, 2001)
and included method linearity, accuracy, precision, recovery, matrix
effects, selectivity, and carryover.
3.5.1 | Calibration, selectivity, and extraction
efficiency
Each standard curve was prepared using eight standards in saliva
or plasma samples in a concentration range from 5.0 to
2000 nmol L1. The coefficient of determination (R2) was >0.99 for
all analyses for plasma and saliva samples (n = 3). The limit of
detection (LOD) was found to be 0.5 nmol L1, and LLOQ was
5.0 nmol L1. Figure 7 shows an LC–MS chromatogram of LLOQ and
blank plasma.
The method selectivity was examined using pooled saliva and
plasma from six different objects. The analysis of the blank sample
(saliva or plasma) was compared with a chromatogram obtained using
a sample from the analysis of RTV at LLOQ to verify the lack of
interfering peaks at the same retention time of the RTV or IS. This
investigation showed that no considerable peaks (≥20% of the LLOQ)
were observed at the same retention time as RTV and the IS. The
method extraction recovery was between 80 and 90%.
3.5.2 | Accuracy and precision
The RE was utilized to assess accuracy, and the precision was
calculated as Coefficient of Variation% of the QC samples. To conduct
the method validation, three assays were prepared, and each assay
consisted of eight calibration points and six QC sample replicates
at three concentration levels: QCL (15.0 nmol L1), QCM
(900 nmol L1), and QCH (1600 nmol L1). For saliva, the accuracy
was found to be in the range of 88.0–106.0% (n = 18), and intra- and
inter-assay precisions were found to be in the range of 0.9–7.4%
(n = 6) and 1.5–5.8% (n = 18), respectively (Table 1). For plasma, the
accuracy ranged from 95 to 108%, and the precision values were 3.2,
5.5, and 6.6 for intra-day precision and 3.4, 4.6, and 5.7 for inter-day
precision (Table 1).
TABLE 1 Accuracy and precision of
QC samples of ritonavir
Accuracy (%) Precision (RSD%)
Intra-day (n = 6) Inter-day (n = 18)Compound Sample (concentration)
Saliva Plasma Saliva Plasma Saliva Plasma
QCL (15.0 nM) 105 108 7.4 6.6 5.8 5.7
Ritonavir QCM (900 nM) 106 102 2.2 5.7 2.5 4.6
QCH (1600 nM) 88.0 95.0 0.9 3.2 1.5 3.4
Note. QCH, high quality control, QCL, low quality control; QCM, medium quality control; RSD, relative standard
deviation.
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3.5.3 | Selectivity and matrix effects
The selectivity was studied by comparing LC–MS chromatogram of
the blank (saliva/plasma) sample with an LLOQ sample. The blank
sample of saliva and plasma did not show any interfering peaks near
the retention time of RTV and the IS (Figure 7).
The effect of the matrix on the MS signal was assessed using the
post-extraction addition method. The blank sample (saliva/plasma)
was extracted accordingly followed by the addition of RTV to the
extract at two concentration levels (QCL and QCH). The results were
then compared with pure standards containing the same concentra-
tions of RTV. It was found that the saliva and plasma matrices did
not affect the detector signal to any observable level. Matrix
effects ranged from 3 to 1% for saliva matrix and from 4 to 5%
for plasma.
3.5.4 | Carryover and reuse of GO-Tabs
The GO-Tabs were washed first with methanol and then with water
after each extraction cycle to reduce any carryover. Using this wash-
ing step, no carryover could be detected. In addition, the GO-Tabs
could be reused for 10 extractions without any observable change in
extraction efficiency. Figure 8 shows LC–MS chromatograms of the
1st and the 10th extraction of RTV in saliva using a single tablet.
4 | METHOD COMPARISON
The results obtained from this present study were compared to those
of earlier-published studies (Table 2). The present method has similar
accuracy and precision measurements with an enhancement of LOQ.
TABLE 2 Comparison of LOD, LLOQ extraction time, and accuracy between this method and earlier-published results
Matrix
Study I (Temghare et al., 2009) Study II (Burugula et al., 2012) Present study
Plasma Plasma Plasma
Sample volume (μL) 200 200 200
Analytical method LC–MS/MS LC-MS/MS LC–MS/MS
Extraction method SPE SPE GO-Tab
Linear range (ng mL–1) 20-3000 8–1600 5–2000
LLOQ (ng mL–1) 20.0 8.0 5.0
Accuracy (%) 98–103 93–99 95–108
Precision (%CV) 2.1–9.6 3.0–6.2 3.4–5.7
Note. GO-Tab, graphene oxide–based tablets; LLOQ, lower limit of quantitation; LOD, limit of detection; SPE, solid-phase extraction.
F IGURE 8 First and 10th extractions using same tablet
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In addition, the present method is easy to handle, and less solvent is
required compared to the reported SPE methods (Burugula, Pilli,
Makula, & Srinivas, 2012; Temghare, Shetye, & Joshi, 2009).
5 | CONCLUSIONS
In this study, GO-Tabs were prepared and used for the extraction
of RTV from human saliva and plasma samples. The GO was
functionalized with amine groups using poly(ethylene glycol)bis
(3-aminopropyl) terminated. The functionalized graphene
(GO-PEG-NH2) was absorbed into a film of polyethylene using an
ultrasonic bath. The validation confirmed that the GO-Tab technique
is accurate and precise for the determination of RTV in human saliva
and plasma samples with good sensitivity. The GO-Tabs could be
reused for at least 10 extractions. The method is rapid and accurate
for the determination of RTV in plasma and saliva samples. The
present study improved the limit of quantification of RTV compared
to earlier studies.
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